Browse by Series:

FDA Approval for Lutathera in Neuroendocrine Tumors

Gina Columbus
Published: Friday, Jan 26, 2018



Gina Columbus reports on the FDA approval to Lutathera (177Lutetium DOTA-octreotate) for the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Slider Left
Slider Right


Gina Columbus reports on the FDA approval to Lutathera (177Lutetium DOTA-octreotate) for the treatment of patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x